

Title (en)

MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE

Title (de)

PHARMAZEUTISCHE FORMULIERUNG MIT MODIFIZierter FREISETZUNG MIT HYDROXYPROPYLCELLULOSE

Title (fr)

FORMULATION PHARMACEUTIQUE À LIBÉRATION MODIFIÉE COMPRENANT DE L'HYDROXYPROPYLCELLULOSE

Publication

EP 4142718 A1 20230308 (EN)

Application

EP 21795764 A 20210428

Priority

- US 202063019215 P 20200501
- US 2021029581 W 20210428

Abstract (en)

[origin: WO2021222369A1] The present disclosure relates to hydroxypropyl cellulose (HPC) having a molar substitution of from about 3.0 to about 3.9, a weight average molecular weight of from about 800,000 to about 2,000,000 Daltons, and a volume average particle size of less than 100 µm, and modified release formulations derived therefrom.

IPC 8 full level

A61K 31/437 (2006.01); **A61K 31/44** (2006.01); **A61K 31/4439** (2006.01)

CPC (source: EP IL KR)

A61K 9/2054 (2013.01 - EP IL KR); **A61K 31/192** (2013.01 - EP IL KR); **A61K 31/5415** (2013.01 - KR); **A61K 31/549** (2013.01 - EP IL KR); **A61K 47/38** (2013.01 - EP IL KR); **C08B 11/08** (2013.01 - EP KR); **C08L 1/284** (2013.01 - EP)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2021222369 A1 20211104; BR 112022022107 A2 20230228; CA 3176772 A1 20211104; CN 115996718 A 20230421; EP 4142718 A1 20230308; EP 4142718 A4 20240529; IL 297810 A 20221201; JP 2023524517 A 20230612; KR 20230005317 A 20230109; MX 2022013552 A 20221130

DOCDB simple family (application)

US 2021029581 W 20210428; BR 112022022107 A 20210428; CA 3176772 A 20210428; CN 202180045957 A 20210428; EP 21795764 A 20210428; IL 29781022 A 20221030; JP 2022566421 A 20210428; KR 20227041714 A 20210428; MX 2022013552 A 20210428